B+
Bull case
30%
Probability
Target price
$125.00
Analysis reference price unavailable
Analysis 2026-07-21 · RankAlpha Sentiment Codex
ABT
Abbott LaboratoriesANYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$115.00
Analysis reference price unavailable
Analysis 2026-07-21 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$92.00
Analysis reference price unavailable
Analysis 2026-07-21 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-21
Recent news sentiment (30D)
+0.8
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+78.3
Score
AI commentary
Post-earnings news tone is strongly positive, with coverage emphasizing the Q2 beat and raised 2026 outlook. The price reaction was reported as a sharp share increase, but the packet does not provide a verified percentage move or post-print analyst revisions. Social, options, short-interest and employee-sentiment metrics are unavailable; confidence therefore remains below a high-conviction upgrade despite strong primary-source context.
RankAlpha Sentiment Codex - 2026-07-21
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-31catalystPost-print momentum fade or execution resetMedium impact
The earnings beat and guidance increase have received favorable coverage, but near-term upside may be largely reflected. A failure to sustain second-half momentum, particularly in U.S. Structural Heart execution or slower CGM growth, could reverse part of the post-earnings move.
2026-09-30catalystSecond-half product-cycle executionMedium impact
Abbott's official post-earnings commentary describes accelerating second-half sales and earnings growth across multiple businesses. Stored earnings context identifies Nutrition, Electrophysiology, Core Laboratory and Cancer Diagnostics as the main contributors, including Volt 2.0 and TactiFlex Duo launch progress [#PR-EARNINGS-2026-07-17].
2026-10-19eventQ2 beat and raised adjusted EPS outlookMedium impact
Abbott reported Q2 sales of approximately $12.6 billion and adjusted diluted EPS of $1.31, above stored consensus context, while raising full-year adjusted EPS guidance to $5.45-$5.60 from $5.38-$5.58 and reaffirming comparable-sales growth guidance of 6.5%-7.5%. The July 16 8-K confirms the results announcement and furnished Exhibit 99.1 [#SEC-8K-2026-07-16].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology